1492 science jobs found in Deerfield, IL

At Lundbeck, we are tirelessly dedicated to restoring brain health so every person can be their best. Headquartered in Copenhagen with a U.S. home office in Deerfield, Ill., Lundbeck is the only global biopharmaceutical company focused solely on brain diseases.

Developing innovative therapies is one of the most challenging, most essential and personally rewarding fields in science. Everything we do is led by our company values of integrity, being patient centric, taking ownership, delivering results and communicating openly. These values are essential to Astellas’ relationship with its employees. Our people humanize us, grow us, are the heart of everything we create and do with integrity. So bring your unique experience, perspective, thinking and ideas.

We Create Medicines and Solutions That Make a Real Difference But it’s more than what we discover—it’s how we get there. WHO WE ARE Meeting the needs of our times AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

At AstraZeneca our mission is to create an inclusive and equitable environment, where people feel they belong. Our ongoing commitment to inclusion and diversity means we’re future proofing our business. It allows us to push the boundaries of science and deliver life-changing medicines to more and more patients around the world.

We Create Medicines and Solutions That Make a Real Difference But it’s more than what we discover—it’s how we get there. WHO WE ARE Meeting the needs of our times AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

At LEO Pharma, we are pioneering together. We help people with skin diseases live fulfilling lives by advancing dermatology beyond the skin.

We are a focused biopharma company. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/immunology and oncology).

Established in 2006 by the merger of two 100-year-old Japanese pharmaceutical companies, Daiichi Sankyo, Inc. is headquartered in New Jersey. The organization includes U.S. commercial operations and global drug development. We offer a unique blend of an entrepreneurial environment and a collaborative culture, and the innovation that propels us forward comes from all corners of our company. At Daiichi Sankyo, good ideas don't just happen in the lab, but also in conference rooms, at desks and in the field, contributed both by individuals and groups.

We Create Medicines and Solutions That Make a Real Difference But it’s more than what we discover—it’s how we get there. WHO WE ARE Meeting the needs of our times AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

We Create Medicines and Solutions That Make a Real Difference But it’s more than what we discover—it’s how we get there. WHO WE ARE Meeting the needs of our times AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

We Create Medicines and Solutions That Make a Real Difference But it’s more than what we discover—it’s how we get there. WHO WE ARE Meeting the needs of our times AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve. 

Baxter is on a journey to separate our ~$5B Kidney Care segment into a standalone company. Vantive* will build on our nearly 70-year legacy in acute therapies and home and in-center dialysis to provide best-in-class care to the people we serve.